Drug Profile
Research programme: VLA-4 antagonists - Elan/Wyeth
Alternative Names: Alpha-4 beta-1 integrin antagonists research programme - Elan/Wyeth; Research programme: alpha-4 beta-1 integrin antagonists - Elan/Wyeth; VLA-4 antagonists research programme - Elan/WyethLatest Information Update: 10 Feb 2005
Price :
$50
*
At a glance
- Originator Elan Corporation
- Developer Elan Corporation; Wyeth
- Class Small molecules
- Mechanism of Action Integrin alpha4beta1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection
Most Recent Events
- 10 Feb 2005 No development reported - Preclinical for Asthma in USA (unspecified route)
- 10 Feb 2005 No development reported - Preclinical for Multiple sclerosis in USA (unspecified route)
- 10 Feb 2005 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)